Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target ...

This increase correlated with changes in biomarkers associated with neurodegenerative diseases like Alzheimer’s, such as ...

Neuroscientists believe that the presence of amyloid-beta is one of the key hallmarks of Alzheimer's. Research indicates that ...

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

This is crucial as the trial’s focus on TREM2 activation, which plays a role in the Amyloid beta pathway associated with Alzheimer’s, could lead to beneficial impacts on brain health beyond amyloid ...

Hilary Evans-Newton is the Chief Executive of Alzheimer’s Research UK. Hilary joined Alzheimer’s Research UK in 2013 and has overseen significant growth in income in recent years, which has ...

In JAMA Neurology, the group challenged the "movement" to define Alzheimer's disease as a "purely biological entity based on biomarker findings." ...

Welcome to the Lantheus Third Quarter 2024 Conference Call. All lines have been placed on mute. This call is being recorded and a replay will be available in the Investors section of the company's ...

Dr. Schacterle is a highly regarded leader who has successfully led global regulatory and quality activities across multiple neurologic and psychiatric therapeutic areas and all stages of development, ...